Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: out_of_the_loop who wrote (3180)	11/8/2000 9:32:17 PM
From: StockDung	Read Replies (1) \| Respond to of 5582

3 The new evidence consisted of testimony from NASD employees Don Johnson and Lisa Chaney about the delisting of GLAD, and a tape-recorded telephone conversation between Carlson and Brett Bouchy ("Bouchy"), another individual from whom the staff alleged that Carlson attempted to obtain stock at below-market prices. nasdr.com

To: out_of_the_loop who wrote (3180)	11/8/2000 9:49:40 PM
From: out_of_the_loop	Read Replies (1) \| Respond to of 5582

repost due to server trouble This board abbreviated: People are here telling lies about Gum-Tech and comparing it to Quigley. 1. GUMM has three main product lines. a. Zicam - most of the zinc-related posts here that relate to oral zinc are immaterial to nasal zinc in a gel. This is for several reasons, one of which is that 2 studies that have been peer-reviewed, only one printed, have shown over 75% improvement in cold symptoms and reduction of cold duration. Most people I know who have tried it have said it works for them and works as advertised. The argument that one possible strain of the rhinovirus could have been responsible for all those infections is not only highly unlikely, it is even more unlikely because two studies, not one, have shown it to work. The arguments about zinc solutions being ineffective are irrelevant because they do relate to gels. Also, saying zinc could never work is analagous to saying lidocaine has no effects as a heart medicine because it is a local anesthetic. Site of action and mode of delivery matter. b. functional gum, including dental gum - the bottom line has not been good as of yet, BUT management has stated the there will be a finalization of a lucrative dental gum contract "very soon". Speculation as to the partner is reasonable to be PG or Colgate since they are leaders in the field and that is who presently lack market presence. Management has been accused by shorts of hyping but they are exactly the opposite and anything you see here from pre-Kehoe just does not apply to current management. c. nicotine gum - the contract for a joint venture has been signed with Swedish Match has been signed, is generous to GUMM and should ship product in Q1 2001. Swedish Match has distribution in 140 countries and is a billion-dollar company. GUMM will not go down the tubes with this partner there anyway. 2. The comparisons to Quigley ignore the different product lines and the way the two companies are set up. Guy Quigley makes over 7 figures and his staff is paid ahndsomely. GUMM execs are paid much less - the companies are very different form the inside out. 3. The argument that GUMM is a stock promotion scheme is one of the most ridiculous things I have ever heard. There are fewer than 10 million shares out there - yes, more than there were three years ago, but if they really wanted to promote stock, they would have a lot more by now. 4. Spam, hype, irrelevancy and obfuscation - as well as ignoring facts - are much more prevalent from the shorts here than from the longs.